Table 1.

Estrogen use (either from estrogen or estrogen + progesterone combination products) among women of the MEDALZ study

	AD, N = 46,116	No AD, N = 46,116
Estrogen use, n (%)
No use in 1995–2012	39,764 (86.2)	39,836 (86.4)
Discontinued before index date	4926 (10.7)	4303 (9.3)
Use before and after index date	1267 (2.8)	1815 (3.9)
Use after index date only	159 (0.3)	162 (0.4)
Use of combination products, n (%)
Discontinued before index date	0	0
Use before and after index date	1140 (2.5)	1116 (2.4)
Use after index date only	6 (0.01)	6 (0.01)
Mean age (95% CI) of incident and prevalent users	74.4 (74.0–74.9)	74.1 (73.7–74.5)
Prevalent	73.9 (73.4–74.3)	73.9 (73.5–74.3)
Incident	78.7 (77.2–80.2)	76.4 (74.6–78.2)
Mean (95% CI) time lag between index date and last purchase after index date (years)	1.91 (1.75–2.08)	2.37 (2.23–2.51)
Median (95% CI) time to discontinuation after index date (years)	1.33 (1.22–1.41)	2.42 (2.28–2.56)
34–55-year-olds, n AD = 32, n non-AD = 59	2.33 (1.15–3.32)	2.88 (2.07–3.34)
56–70-year-olds, n AD = 412, n non-AD = 535	1.80 (1.55–1.96)	2.71 (2.55–3.00)
71–80-year-olds, n AD = 597, n non-AD = 904	1.33 (1.17–1.46)	2.55 (2.38–2.71)
81–90-year-olds, n AD = 364, n non-AD = 451	0.79 (0.65–0.99)	1.75 (1.62–2.00)
91–97-year-olds, n AD = 21, n non-AD = 28	0.85 (0.28–1.52)	2.05 (1.29–2.78)
Reason for ending the estrogen use among incident and prevalent users, n (% of users)
Use period ended	1019 (71.5)	1168 (59.1)
Death	53 (3.7)	46 (2.3)
90+ days hospitalization/institutionalization	99 (6.9)	30 (1.5)
End of data linkage	255 (17.9)	733 (37.1)

AD Alzheimer’s disease, CI confidence interval, MEDALZ Medication and Alzheimer’s Disease